This study follows 75 people with Gaucher disease type 1 who already received an experimental gene therapy called FLT201. Researchers will monitor them for 5 years to see if the treatment remains safe and if its effects last. The goal is to understand long-term risks and benefits…
Phase: PHASE1, PHASE2 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated May 07, 2026 18:43 UTC